| 2.48 Data as of May 20 |  -0.03 / -1.20%Today’s Change | 1.74 Today|||52-Week Range 5.10 | -12.98% Year-to-Date |
| Wider-than-Expected Loss at Dynavax - Analyst Blog May 07 / Zacks.com |
| Previous close | 2.51 |
| Today’s open | 2.50 |
| Day’s range | -- - -- |
| Volume | 1,810,529 |
| Average volume (3 months) | 2,786,863 |
| Market cap | $459.1M |
| Dividend yield | -- |
| Earnings growth (last year) | -5.13% |
| Earnings growth (this year) | 0.00% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -55.06% |
| P/E ratio | NM |
| Price/Sales | 50.01 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| SGNTSagent Pharmaceutica... | +0.34 | +2.09% |
| NDZNordion Inc | -0.13 | -1.78% |
| SCRSimcere Pharmaceutic... | +0.03 | +0.32% |
| HITKHi-Tech Pharmacal Co... | +0.68 | +2.11% |
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | -$0.10 |
| Annual revenue (last year) | $9.7M |
| Annual profit (last year) | -$69.9M |
| Net profit margin | -720.08% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Dino Dina, MD |
President, Director & Chief Medical Officer J. Tyler Martin, MD |
Corporate headquarters Berkeley, California |
.
